IXHL
HEALTHCAREIncannex Healthcare Ltd
$4.91+0.16 (+3.37%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IXHL Today?
No stock-specific AI insight has been generated for IXHL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.40$49.80
$4.91
Fundamentals
Market Cap$69M
P/E Ratio—
EPS$-22.20
Dividend Yield—
Dividend / Share—
ROE-1.3%
Profit Margin—
Debt / Equity—
Trading
Volume232K
Avg Volume (10D)—
Shares Outstanding14.0M
IXHL News
20 articles- Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental IllnessYahoo Finance·Apr 22, 2026
- Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic PositionYahoo Finance·Mar 27, 2026
- Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea ResearchYahoo Finance·Mar 25, 2026
- Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X DevelopmentYahoo Finance·Mar 18, 2026
- Incannex Regains Compliance with Nasdaq Minimum Bid Price RequirementYahoo Finance·Mar 17, 2026
- Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesYahoo Finance·Mar 12, 2026
- Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 OutcomesYahoo Finance·Mar 12, 2026
- Incannex Healthcare Inc. (IXHL) Implements 1-for-30 Reverse Split Effective February 26Yahoo Finance·Mar 3, 2026
- Incannex Announces Reverse Stock SplitYahoo Finance·Feb 25, 2026
- Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026Yahoo Finance·Feb 18, 2026
- Incannex Healthcare Announces Additional Appointments to Clinical Advisory BoardYahoo Finance·Jan 29, 2026
- Weekly Roundup on the Cannabis Sector & Psychedelic SectorYahoo Finance·Jan 26, 2026
- Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 ProgramYahoo Finance·Jan 22, 2026
- Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence AwardsYahoo Finance·Jan 15, 2026
- Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026Yahoo Finance·Jan 14, 2026
- Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)Yahoo Finance·Dec 3, 2025
- What Makes Incannex Healthcare Inc. (IXHL) a New Buy StockYahoo Finance·Dec 1, 2025
- Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026Yahoo Finance·Nov 20, 2025
- Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic FocusYahoo Finance·Oct 30, 2025
- Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementYahoo Finance·Oct 22, 2025
All 20 articles loaded
Price Data
Open$4.69
Previous Close$4.75
Day High$4.98
Day Low$4.64
52 Week High$49.80
52 Week Low$2.40
52-Week Range
$2.40$49.80
$4.91
Fundamentals
Market Cap$69M
P/E Ratio—
EPS$-22.20
Dividend Yield—
Dividend / Share—
ROE-1.3%
Profit Margin—
Debt / Equity—
Trading
Volume232K
Avg Volume (10D)—
Shares Outstanding14.0M
About Incannex Healthcare Ltd
Incannex Healthcare Limited is engaged in the research, development and sale of medicinal cannabinoid products in Australia. The company is headquartered in Sydney, Australia.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—